Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01154127 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: NVA237
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals